Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Considering buying TSLA stock? Here’s what analysts think: Read This Next: Photo via ShutterstockLoading...Loading... ...

Co-Diagnostics (CODX) announced that it has signed a strategic Memorandum of Understanding with a regional manufacturing and distribution company located in the Kingdom of Saudi Arabia, to explore a joint venture that would be granted a license to develop, manufacture, and sell Co-Dx intellectual property throughout the Middle East and North Africa, including the company’s upcoming Co-Dx PCR point-of-care platform. According to the MOU, the KSA partner company in the JV would contribute local operational s ...

Co-Diagnostics Inc. CODX shares dropped 28.26% to $0.46 in pre-market trading on Tuesday, wiping out the gains from Monday’s 80.76% surge, which had closed at $0.64, according to Benzinga Pro data.Check out the current price of CODX stock here.Strategic Partnership Fails to Sustain MomentumThe molecular diagnostics firm revealed it has signed a Memorandum of Understanding with a Saudi Arabian partner to potentially create a joint venture aimed at developing and distributing its Co-Dx™ PCR platform technolog ...

Accessibility StatementSkip Navigation As of July, there have been nearly 250,000 cases and 90 deaths from CHIKV worldwide, primarily concentrated in South America, but also found in countries across Africa, Asia and Europe. An estimated 5.6 billion people currently live in at-risk areas across 119 countries as warming trends contribute to expanded regions for the mosquitoes that can carry CHIKV. Chikungunya imposes a significant economic burden, especially in low- and middle-income countries. Long- term co ...

Core Insights - Co-Diagnostics, Inc. has been recognized at the Utah Business 2025 Innovation Awards Summit for its Co-Dx PCR platform in the Healthcare and Life Sciences category [1][2] - The award was accepted by CEO Dwight Egan, highlighting the company's innovative approach to molecular diagnostics [2][3] - The Co-Dx PCR platform aims to improve access to high-quality PCR diagnostics globally, with commercialization expected next year [3] Company Overview - Co-Diagnostics, Inc. is a molecular diagnostics company based in Utah, specializing in the development, manufacturing, and marketing of advanced diagnostic technologies [4] - The company's proprietary technology is utilized for tests designed to detect and analyze nucleic acid molecules (DNA or RNA) [4] - Co-Diagnostics also focuses on creating specific tests for its Co-Dx PCR at-home and point-of-care platform, as well as identifying genetic markers for various applications beyond infectious diseases [4]

Company Overview - Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets advanced diagnostic technologies designed to detect and analyze nucleic acid molecules (DNA or RNA) [6] - The company utilizes proprietary technology to create specific tests for its Co-Dx PCR at-home and point-of-care platform, as well as to identify genetic markers for applications beyond infectious disease [6] Upcoming Events - Co-Diagnostics will host a booth at the 17th Annual Next Generation Dx Summit, taking place both virtually and in-person at the Capital Hilton in Washington, D.C. from August 18-20, 2025 [1] - Attendees are encouraged to visit Booth 12 to learn about the Co-Dx Logix Smart® suite of clinical laboratory solutions and the upcoming Co-Dx PCR diagnostics platform, which includes tests for upper respiratory infections, tuberculosis, and HPV, expected to enter clinical evaluations in 2025 [3] Industry Context - The Next Generation Dx Summit serves as a platform for international thought leaders to network and discuss advancements in diagnostics and technology innovation, focusing on areas such as point-of-care testing, decentralized testing, infectious diseases, liquid biopsy, and companion diagnostics [2]

Core Viewpoint - Co-Diagnostics, Inc. reported its financial results for Q2 2025, highlighting developments in its Co-Dx PCR testing platform and the need for regulatory approval before market availability [2][3]. Financial Results - The company released its financial results for the second quarter ended June 30, 2025, which are available on its website [2]. Management Remarks - The conference call included prepared remarks from the CEO Dwight Egan and CFO Brian Brown, followed by a Q&A session with analysts [2]. Forward-Looking Statements - The company made forward-looking statements regarding its Co-Dx PCR testing platform, emphasizing that it requires regulatory approval and is not currently for sale [3][4].

Core Viewpoint - Co-Diagnostics, Inc. reported a quarterly loss of $0.23 per share, which was better than the Zacks Consensus Estimate of a loss of $0.25, indicating an earnings surprise of +8.00% [1] Financial Performance - The company posted revenues of $0.16 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 45.67%, and a significant decline from $2.66 million in the same quarter last year [2] - Over the last four quarters, Co-Diagnostics has surpassed consensus EPS estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $0.3 million, and for the current fiscal year, it is -$0.68 on revenues of $0.95 million [7] Stock Performance - Co-Diagnostics shares have declined approximately 64.9% since the beginning of the year, contrasting with a 10% gain in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical Services industry, to which Co-Diagnostics belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 decreased to $200,000 compared to $2,700,000 in the same period last year, with revenue from grants in the prior year being $2,500,000 [17] - Total operating expenses decreased to $8,200,000 from $10,100,000 in the prior year, reflecting efforts to improve operational efficiency [17] - Net loss for Q2 2025 was $7,700,000, or a loss of $0.23 per fully diluted share, compared to a net loss of $7,600,000, or a loss of $0.25 per fully diluted share in the prior year [18] - Adjusted EBITDA loss increased to $7,200,000 from $5,900,000 in the previous year [18] - Cash, cash equivalents, and marketable investment securities at the end of Q2 2025 totaled $13,400,000 [18] Business Line Data and Key Metrics Changes - The Kodiak PCR platform is on track to initiate clinical evaluations for all tests in the pipeline during 2025, including tests for COVID-19, flu, tuberculosis, and HPV [5][6] - The Kodiak PCR ABCR four-plex respiratory panel is expected to begin clinical evaluations concurrent with the 2025 North American flu season [9] - The company is focusing on the tuberculosis test, which is expected to begin clinical evaluations in India and South Africa before the end of 2025 [7][8] Market Data and Key Metrics Changes - India accounted for 27% of global TB cases and 26% of global TB deaths in 2023, making it a top priority market for the company's TB testing [8] - The company aims to target primary healthcare facilities in India, where there are nearly 30,000 centers that require advanced molecular technology [34] Company Strategy and Development Direction - The company is committed to increasing the accessibility of affordable, high-quality diagnostics in the U.S., India, and globally [6] - Plans include expanding manufacturing capacity domestically and in India to meet market demand upon platform launch [16] - The company is pursuing a commercialization strategy targeting physician offices, clinics, skilled nursing facilities, and pharmacies in the U.S. [30][34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for multiple commercial launches in 2026 and future developments within the test pipeline [19] - The company anticipates that the clinical trial for the COVID-19 test will be completed by year-end 2025, with a reasonable possibility of FDA clearance by mid-2026 [36][37] Other Important Information - The company is managing its capital requirements through equity or debt financing, additional grant funding, and operational efficiencies [19] - The Kodiak PCR platform is expected to revolutionize PCR infectious disease testing by enhancing affordability, accessibility, and decentralization [16] Q&A Session Summary Question: Expected timeline for clinical trials and applications - Management expects all four tests to enter clinical trials during the remainder of 2025, starting with the COVID-19 test [23] Question: Commercial launch visibility and marketing strategy - Commercialization is planned as soon as FDA clearance is obtained, targeting physician offices, clinics, and pharmacies in the U.S. [30][34] Question: Timeline for commercialization - Management hopes for commercialization before 2026, with a possibility of FDA clearance by mid-2026 [36][37]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File No. 001-38148 CO-DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorpora ...